BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Preclinical study evaluated melanocortin 1 receptor (MC1R) as a potential target for MC1R-targeted therapies for metastatic melanoma, the lead target of VMT01 -
- Results indicate that MC1R-targeted
Share
Photo: (Photo : Photo by Anna Shvets from Pexels)
A brain tumor is the primary cause of cancer-related fatalities in children and second most common to teens, but a unique treatment is coming.
Brain tumors are the increasing cause of cancer-related fatalities in children under the age of ten and the second most common cause of cancer deaths in people under twenty. While brain cancer remains one of the most challenging cancers to treat, researchers at Dana Farber/Boston Children s Cancer and Blood Disorders Center significantly improve survival rates in the coming years.
While survival rates for children with some forms of brain tumors have improved significantly in the last 30 years, current research aims to increase those rates in the coming years mainly. Scientists are concentrating their efforts on the fundamental genetic and genomic errors that cause tumors, as well as the components of the tumor s microenvironment.
Share this article
Share this article
BOTHELL, Wash., April 13, 2021 /PRNewswire/ Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics), an emerging biotechnology company focused on developing a novel MabPair
™ platform for antibody-based combination therapies for the treatment of cancer, inflammation and autoimmune disease, announced a clinical update on its first MabPair product PSB205 at the American Association for Cancer Research (AACR) Annual Meeting. Dr Li Zhang of Sun Yat-Sen University Cancer Centre (SYSUCC), Guangzhou, China presented a poster on Phase 1 Clinical Trial results of PSB205, a combination of anti-PD1 and anti-CTLA-4 antibodies that are manufactured together as a single product, in patients with advanced malignant tumors. The study is sponsored by Qilu Pharma in China.
Viewpoint Molecular Targeting(TM) Presents Positive Preclinical Results of VMT01 at the 2021 American Association for Cancer (AACR) Annual Meeting phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.